SLTT entities may lack the capability to immediately provide sufficient care and MCMs in the aftermath of a biological incident. MCM distribution may be challenging due to limited availability, overwhelming demand, and requests beyond impacted areas. Available MCMs should be prioritized for healthcare facilities. Closed PODs may be necessary to set up within hospitals to provide patients and staff with MCMs, where appropriate. If closed PODs are established to provide healthcare personnel with MCMs, the public should be informed not to go to hospitals for MCMs unless specifically instructed to do so due to the potential to overwhelm hospital systems.
Over time, individuals receiving MCMs (or having received them in the past) may perceive to be experiencing adverse effects associated with treatment. While there is not necessarily an increased risk of adverse effects from MCMs compared to that of any medical treatment, all persons concerned about possible adverse effects resulting from MCM administration should seek medical attention and follow up with their healthcare provider to fully investigate their concerns. Medical care related to addressing adverse effects from MCMs is supported by the Public Health Readiness and Emergency Preparedness Act (PREP) Act.